Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Team Grant: E-Rare Joint Transnational Call

McGill University

$256,250.00

REALS: Testing the safety of repurposed Enoxacin for the treatment of Amyotrophic Lateral Sclerosis

EF 2016-17

Résumé
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a rare progressive and ultimately fatal degenerative disease, affecting both upper and lower motor neurons in the brain and spinal cord. ALS is characterized by a progressive loss of voluntary motor activity, including speech, swallowing and respiratory function with an average survival time of 2 to 5 years. There is a clear unmet need to test new therapies for ALS since current treatments are extremely limited. Enoxacin is an oral broad-spectrum antibiotic that has been approved and marketed for more than 20 years for bacterial infections. Enoxacin has been show to increase activity of Dicer, a key endoribonuclease essential for microRNA maturation. miRNAs have been shown to be dysregulated in motorneurons from ALS patients. Our plan is to test Enoxacin in ALS patients . The primary Endpoint is first in patient study of Enoxacin toxicity and safety in subjects with probable or definite ALS. The secondary endpoints are pharmacokinetic (PK) and development of a pharmacodynamic (PD) marker to reveal target engagement.
Programme
Team Grant: E-Rare Joint Transnational Call
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
349080
Name
Genge Angela L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
German Federal Ministry of Research, Technology and Space (Berlin); Israeli Ministry of Health; Fonds de recherche du Québec - Santé (FRQS); Fonds de recherche du Québec - Santé (FRQS)
Instname2
Musculoskeletal Health and Arthritis
Theme2
Clinical
Prcname2
Special Cases
Projecttitle
REALS: Testing the safety of repurposed Enoxacin for the treatment of Amyotrophic Lateral Sclerosis
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$256,250
Cihrequipment2
$0
Programname2
Team Grant: E-Rare Joint Transnational Call
Keyworddelim
Amyotrophic Lateral Sclerosis (Als); Csf; Enoxacin; Mirna; Pharmacodynamics; Pharmacokinetics; Phase 1 Clinical Trial; Rare Disease; Safety; Tolerability
Abstract
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a rare progressive and ultimately fatal degenerative disease, affecting both upper and lower motor neurons in the brain and spinal cord. ALS is characterized by a progressive loss of voluntary motor activity, including speech, swallowing and respiratory function with an average survival time of 2 to 5 years. There is a clear unmet need to test new therapies for ALS since current treatments are extremely limited. Enoxacin is an oral broad-spectrum antibiotic that has been approved and marketed for more than 20 years for bacterial infections. Enoxacin has been show to increase activity of Dicer, a key endoribonuclease essential for microRNA maturation. miRNAs have been shown to be dysregulated in motorneurons from ALS patients. Our plan is to test Enoxacin in ALS patients . The primary Endpoint is first in patient study of Enoxacin toxicity and safety in subjects with probable or definite ALS. The secondary endpoints are pharmacokinetic (PK) and development of a pharmacodynamic (PD) marker to reveal target engagement.
Competitiondate
201604
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Genge, Angela L
Approvedterm
3 ans 0 mois
Cihrcontribution2
Institute of Genetics~ $256,250~ $0~